NOVO B Novo Nordisk A/S Class B

Novo Nordisk A/S - Vedtægter

Novo Nordisk A/S - Vedtægter

Vedtægter for Novo Nordisk A/S, 2020.

Vedhæftet fil

EN
26/03/2020

Underlying

NOVO BNovo Nordisk A/S Class B

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Novo Nordisk A/S Class B

Rune Majlund Dahl
  • Rune Majlund Dahl
Free Trial
NOVO B Novo Nordisk A/...

Novo Nordisk (Buy, TP: DKK900.00) - Subdued prescription growth in Q1

We have updated our model with the latest IQVIA data, and see downside risk to Visible Alpha consensus. We see Q1e global sales for Wegovy of DKK17,898m (c2.2% below consensus) and Ozempic of DKK31,642m (c1.5% below consensus). While a reaffirmation of guidance could offer relief, we have lowered our target price, primarily on lower-than-expected GLP-1 sales. We reiterate our BUY but have cut our target price to DKK900 (1,040).

NOVO B NOVO NORDISK A/S CLASS B
04/11/25 April 11, 2025 1 EN
Rune Majlund Dahl
  • Rune Majlund Dahl
Free Trial
NOVO B Novo Nordisk A/...

Zealand Pharma (Buy, TP: DKK1150.00) - Deal delivery

We are positive on the partnership with Roche for petrelintide and view the financial terms as favourable for Zealand Pharma. While we had included Roche as the partner for petrelintide in our base case, the deal terms are better than we assumed. Thus, we have updated our valuation for petrelintide to DKK731 NPV/share. We reiterate our BUY and have increased our target price to DKK1,150 (1,010), based on our SOTP NPV.

NOVO B NOVO NORDISK A/S CLASS B
03/13/25 March 13, 2025 1 EN
Rune Majlund Dahl
  • Rune Majlund Dahl
Free Trial
NOVO B Novo Nordisk A/...

Zealand Pharma (Buy, TP: DKK1010.00) - Poised for big news

Q4 revenue was DKK9.1m, driven by the Zegalogue licence and development agreement with Novo Nordisk, and EBIT was DKK-399.3m (we forecast DKK-370.1m, consensus DKK-367.6m). The 2025 opex guidance was for DKK2,000m–2,500m, reflecting pipeline progression investments. We expect strong pipeline news flow in H1, including dapiglutide headline results and potentially a petrelintide partnership. We reiterate our BUY and DKK1,010 target price.

NOVO B NOVO NORDISK A/S CLASS B
02/20/25 February 20, 2025 1 EN
Rune Majlund Dahl
  • Rune Majlund Dahl
Free Trial
NOVO B Novo Nordisk A/...

Zealand Pharma (Buy, TP: DKK1010.00) - Focus on partnership discussion...

We expect an uneventful Q4 report, but with investor focus on the ongoing petrelintide partnership discussions. Our base case derives DKK593/share for petrelintide, assuming a profit-sharing agreement in H1. We believe recruitment for the petrelintide phase II trial will be completed in H1 (headline results in Q1 2026e) and look for 2025 opex guidance of DKK1,750m–1,850m. We reiterate our BUY and DKK1,010 target price.

NOVO B NOVO NORDISK A/S CLASS B
02/11/25 February 11, 2025 1 EN
Free Trial
NOVO B Novo Nordisk A/...

Novo Nordisk AS: 1 director

A director at Novo Nordisk AS sold after exercising options/sold 40,000 shares at 620.260DKK and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors...

NOVO B NOVO NORDISK A/S CLASS B
02/07/25 February 7, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch